Display options
Cite
Holm CP, Holm J, Nørgaard A, et al. COPD, stage and treatment in a large outpatient clinic. Eur Clin Respir J. 2017;4(1):1267470doi: 10.1080/20018525.2017.1267470.
Holm, C. P., Holm, J., Nørgaard, A., & Godtfredsen, N. (2017). COPD, stage and treatment in a large outpatient clinic. European clinical respiratory journal, 4(1), 1267470. https://doi.org/10.1080/20018525.2017.1267470
Holm, Claire Præst, et al. "COPD, stage and treatment in a large outpatient clinic." European clinical respiratory journal vol. 4,1 (2017): 1267470. doi: https://doi.org/10.1080/20018525.2017.1267470
Holm CP, Holm J, Nørgaard A, Godtfredsen N. COPD, stage and treatment in a large outpatient clinic. Eur Clin Respir J. 2017 Jan 04;4(1):1267470. doi: 10.1080/20018525.2017.1267470. eCollection 2017. PMID: 28326174; PMCID: PMC5328358.
Copy Download .nbib Format: NLM
Share it on

Eur Clin Respir J. 2017 Jan 04;4(1):1267470. doi: 10.1080/20018525.2017.1267470. eCollection 2017.

COPD, stage and treatment in a large outpatient clinic.

European clinical respiratory journal

Claire Præst Holm, Jakob Holm, Annette Nørgaard, Nina Godtfredsen

Affiliations

  1. Department of Respiratory Medicine, Copenhagen University Hospital , Hvidovre , Denmark.
  2. Department of Endocrinology, Copenhagen University Hospital , Hvidovre , Denmark.
  3. Lunge- og allergiklinikken , Hellerup , Denmark.

PMID: 28326174 PMCID: PMC5328358 DOI: 10.1080/20018525.2017.1267470

Abstract

Some COPD patients suffer from frequent exacerbations despite triple inhalation treatment. These frequent exacerbators should be identified, as exacerbations often lead to decreasing lung function and increasing mortality. Roflumilast reduces exacerbations in patients with a previous history of exacerbations. Our aim was to describe COPD patient characteristics and compare roflumilast treatment eligible to non-eligible patients. An observational cross-section study was conducted. Patients were included from a large COPD outpatient clinic. Information regarding COPD patient characteristics was registered on a standardized form and lung function was measured. Patients were categorized according to the GOLD classification. Eligibility for roflumilast treatment was assessed and patient characteristics compared between groups. 547 patients were included. Most patients (54%) were in GOLD group D. 62 patients (11.3%) met the criteria for treatment with roflumilast. Among the patients eligible for roflumilast treatment, only 14 patients (22.6%) were receiving treatment. There were no significant differences in FEV

Keywords: COPD; GOLD groups; exacerbations; frequent exacerbator; outpatients; phosphodiesterase-4 inhibitor; roflumilast

References

  1. Thorax. 2002 Oct;57(10):847-52 - PubMed
  2. Thorax. 2005 Nov;60(11):925-31 - PubMed
  3. Chest. 2013 May;143(5):1302-11 - PubMed
  4. Eur Respir J. 2007 Mar;29(3):527-34 - PubMed
  5. Int J Chron Obstruct Pulmon Dis. 2015 May 12;10:909-15 - PubMed
  6. Pulm Pharmacol Ther. 2015 Feb;30:16-21 - PubMed
  7. Am J Respir Crit Care Med. 2013 Aug 1;188(3):271-8 - PubMed
  8. N Engl J Med. 2010 Sep 16;363(12):1128-38 - PubMed
  9. Chest. 2011 Sep;140(3):626-33 - PubMed
  10. Lancet. 2015 Mar 7;385(9971):857-66 - PubMed

Publication Types